Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer
NCT ID: NCT01501669
Last Updated: 2012-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
222 participants
INTERVENTIONAL
2011-06-30
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Capecitabine alone arm: 1250 mg/m2, BID, day 1-14, every 3 weeks
* Irinotecan plus capecitabine arm : Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks + capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks.
Randomization will be done using a random block size permutation method and stratified based on : hormone receptor status (negative vs. positive), first line vs. more than second lines, visceral metastasis (negative vs. positive).
Treatment will continue until disease progression, death, or discontinuation due to side effects of drugs or refusal by patients.
The primary objective of this study is to estimate the PFS of capecitabine and irinotecan in patients with anthracycline and taxane- pretreated metastatic breast cancer, which will be estimated by the Kaplan-Meier method and compared by log-rank test. Overall survival will be also estimated by same method. The secondary statistical analysis consisting of an estimation of the complete and partial response rates and response rates of the treatment will be calculated as the ratio of the number of complete and partial responders to the total number of evaluable patients and toxicity profile, which will be estimated as the ratio of the number of occurrence to the total number of evaluable patients. A 95% confidence interval for the response rate is computed based on the binomial distribution function. The analysis for reporting the final treatment results will be undertaken when each patient has been potentially followed for a minimum of 12 months. The overall survival and progression free survival, and their respective medians will be estimated with 95% confidence intervals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Capecitabine alone arm
X arm
No interventions assigned to this group
Irinotecan plus capecitabine arm
Irinotecan, Capecitabine
Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks
\+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Irinotecan, Capecitabine
Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks
\+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HER2 negative disease, or HER2 unknown disease not eligible for anti-HER2 therapy
* ECOG performance status 0-2
* Age ≥ 20 years
* Patients who received anthracycline based chemotherapy in the (neo)adjuvant or metastatic setting and experienced disease progression on taxane based chemotherapy in the metastatic setting, or patients who experienced disease recurrence within 1 year after completion of (neo)adjuvant anthracycline and taxane based chemotherapy
* In case of patients treated with capecitabine in an adjuvant setting, disease recurrence should not be occurred within 1 year after completion of capecitabine chemotherapy
* Patients with brain metastasis can be enrolled when they don't need any treatment regarding to brain metastasis
* Previous any chemotherapy and radiotherapy should be completed at least 3 weeks before randomization- Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 \[21\]
* Adequate hematopoietic function: absolute granulocyte count ≥ 1,500/mm3, platelet ≥ 100,000/mm3, hemoglobin ≥ 10g/mm3
* Adequate hepatic function: total bilirubin ≤ 1.5mg/dL, alkaline phosphatase(ALP) ≤ 2.5 x UNL, AST/ALT ≤ 2x UNL, or if liver function abnormalities due to underlying malignancy exists, AST/ALT ≤ 2.5 x UNL, total bilirubin ≤ 3.0mg/dL, (ALP) ≤ 5 x UNL in cases with bone metastasis; ALP ≤ 5 x UNL
* Adequate renal function : serum creatinine ≤ 1.5mg/dL
* Ability to understand and comply with protocol during study period
* Patients should sign a written informed consent before study entry
Exclusion Criteria
* Patients who receive irinotecan or capecitabine for metastatic breast cancer treatment
* Patients with HER2 positive breast cancer
* Grade 2 or greater peripheral neuropathy
* Patients with symptomatic brain metastasis
* Prior unanticipated severe reaction to fluropyrimidine therapy or known sensitivity to 5-fluorouracil
* Patients who have history of cancer other than in situ cervical cancer or non-melanotic skin cancer
* Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedure affecting absorption, uncontrolled GI disease (e.g. Crohn's disease, ulcerative colitis)
20 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asan Medical Center
OTHER
Chung-Ang University
OTHER
Inha University Hospital
OTHER
Korea University Anam Hospital
OTHER
Samsung Medical Center
OTHER
Severance Hospital
OTHER
Seoul National University Hospital
OTHER
Seoul National University Bundang Hospital
OTHER
National Cancer Center, Korea
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jungsil Ro
Chief, Center for Clinical Trials, National Cancer Center, Korea
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jungsil Ro
Role: PRINCIPAL_INVESTIGATOR
National Cencer Center, Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jungsil Ro
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCCCTS-11-536
Identifier Type: -
Identifier Source: org_study_id